Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 1:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Benign Prostatic Hyperplasia Clear all
Completed Phase 2 Interventional Results available

Efficacy and Safety of S-Equol on Men With Benign Prostatic Hyperplasia

NCT00962390
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
S-equol, Placebo
Drug
Lead sponsor
Ausio Pharmaceuticals, LLC
Industry
Eligibility
50 Years and older · Male only
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
5
States / cities
Huntsville, Alabama • Aventura, Florida • Clearwater, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated May 18, 2017 · Synced Sep 25, 2026, 1:38 PM EDT
Withdrawn Phase 4 Interventional

The Combined Effect of Intravesical Botox Injections and HoLEP Surgery in Treating Benign Prostatic Hyperplasia and Overactive Bladder

NCT05393921
View directory record Official record
Conditions
Benign Prostatic Hyperplasia, Overactive Bladder
Interventions
Intravesical Botox injection
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
40 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
3
States / cities
Cleveland, Ohio • Lyndhurst, Ohio • Richmond Heights, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 4, 2025 · Synced Sep 25, 2026, 1:38 PM EDT
Terminated Phase 2 Interventional Results available

Prostate Artery Embolization as a Treatment for Benign Prostatic Hyperplasia in Men With Prostates Larger Than 90 Grams

NCT02396420
View directory record Official record
Conditions
Prostatic Hyperplasia
Interventions
Embosphere Microspheres
Device
Lead sponsor
South Florida Medical Imaging, PA
Other
Eligibility
40 Years to 89 Years · Male only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Fort Lauderdale, Florida
Source: ClinicalTrials.gov public record
Updated Nov 5, 2018 · Synced Sep 25, 2026, 1:38 PM EDT
Withdrawn Not applicable Interventional

Innovative Minimally Invasive Options in Treatment of Urinary Problems Related to Prostate Enlargement (BPH) in Men

NCT03043222
View directory record Official record
Conditions
Lower Urinary Tract Symptoms, Benign Prostatic Hyperplasia, Urinary Frequency/Urgency, Urinary Incontinence, Urge, Incontinence, Urinary, Nocturia
Interventions
UroLift as artifical device for prostatic urethral lift., Embospheres Microspheres as embolic agents for prostate artery embolization
Device
Lead sponsor
St. Louis University
Other
Eligibility
40 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 19, 2018 · Synced Sep 25, 2026, 1:38 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Utilization of a Web-Based Application to Improve Patient Health Literacy and Reduce Clinic Visit Times in Holmium Laser Enucleation of the Prostate (HoLEP) Procedures and Kidney Stone Surgery

NCT07580391
View directory record Official record
Conditions
Kidney Stone, Benign Prostatic Hyperplasia
Interventions
WellPrept, Standard Care
Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 100 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Sep 25, 2026, 1:38 PM EDT
Completed Phase 2 Interventional

Phase 2 Study of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) (Enlarged Prostate)

NCT00759135
View directory record Official record
Conditions
Benign Prostatic Hyperplasia (BPH), Enlarged Prostate
Interventions
2.5 mg NX-1207, 0.125 mg NX-1207, finasteride
Drug
Lead sponsor
Nymox Corporation
Industry
Eligibility
45 Years to 75 Years · Male only
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
30
States / cities
Huntsville, Alabama • Tucson, Arizona • Little Rock, Arkansas + 27 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2012 · Synced Sep 25, 2026, 1:38 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Comparative Bioavailability of Two Fixed Dose Combination (FDC) Formulations of Dutasteride and Tamsulosin Hydrochloride Relative to Co-administration of Dutasteride With Tamsulosin Hydrochloride in Healthy Male Subjects Under Fed and Fasted States

NCT02184585
View directory record Official record
Conditions
Prostatic Hyperplasia
Interventions
Treatment sequence A, Treatment sequence B, Treatment sequence C
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 18, 2018 · Synced Sep 25, 2026, 1:38 PM EDT
Terminated Phase 2 Interventional

Photodynamic Therapy (PDT) for Lower Urinary Tract Symptoms (PLUS)

NCT00116571
View directory record Official record
Conditions
Prostatic Hyperplasia
Interventions
Lemuteporfin for injection, Transurethral drug delivery system, Transurethral light delivery system
Drug · Device
Lead sponsor
QLT Inc.
Industry
Eligibility
21 Years and older · Male only
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
8
States / cities
San Bernardino, California • Shreveport, Louisiana • Greenbelt, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2006 · Synced Sep 25, 2026, 1:38 PM EDT
Terminated Phase 3 Interventional Results available

Cetrorelix (CET) Pamoate Regimens in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)

NCT00449150
View directory record Official record
Conditions
Benign Prostatic Hypertrophy
Interventions
Cetrorelix 78 mg + 78 mg, Cetrorelix 78 mg + 52 mg, Placebo
Drug
Lead sponsor
AEterna Zentaris
Industry
Eligibility
50 Years and older · Male only
Enrollment
667 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
46
States / cities
Huntsville, Alabama • Fort Smith, Arkansas • Laguna Hills, California + 39 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2018 · Synced Sep 25, 2026, 1:38 PM EDT
Not listed Not applicable Interventional

Benign Prostatic Hyperplasia and Prostate Size Greater Than 90 Grams

NCT02167009
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
Embosphere Microspheres
Device
Lead sponsor
Tampa General Hospital
Other
Eligibility
50 Years to 85 Years · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 9, 2019 · Synced Sep 25, 2026, 1:38 PM EDT
Completed Not applicable Interventional Results available

Prostatic Artery Embolization (PAE) for Treatment of Signs and Symptoms of Benign Prostatic Hyperplasia (BPH) Using Bead Block Microspheres

NCT03052049
View directory record Official record
Conditions
Benign Prostatic Hyperplasia (BPH)
Interventions
Prostate Artery Embolization
Device
Lead sponsor
Northwestern University
Other
Eligibility
45 Years and older · Male only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 9, 2023 · Synced Sep 25, 2026, 1:38 PM EDT
Completed Phase 2 Interventional

A Placebo Controlled Study of MR901 (Talaporfin Sodium Sodium + a Drug-activating Device) for the Relief of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia

NCT02326454
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
talaporfin sodium, Saline, Drug Activator 100 J/cm, Drug Activator 200 J/cm
Drug · Device
Lead sponsor
Light Sciences Oncology
Industry
Eligibility
40 Years and older · Male only
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
41
States / cities
Anniston, Alabama • Huntsville, Alabama • Anchorage, Alaska + 37 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2018 · Synced Sep 25, 2026, 1:38 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Moses 2.0 vs Magneto for HoLEP - a Randomized Controlled Trial

NCT07632742
View directory record Official record
Conditions
Enlarged Prostate (BPH), Benign Prostatic Hyperplasia
Interventions
Magneto 150 holmium laser, Moses 2.0 holmium laser
Device
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 100 Years · Male only
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Sep 25, 2026, 1:38 PM EDT
Recruiting Not applicable Interventional

PRescription Exercise for Older Men With Urinary Disease

NCT06225479
View directory record Official record
Conditions
Lower Urinary Tract Symptoms, Benign Prostatic Hyperplasia
Interventions
Exercise, Calls and Newsletter
Behavioral · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
60 Years and older · Male only
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 16, 2025 · Synced Sep 25, 2026, 1:38 PM EDT
Terminated Phase 2 Interventional

Study of the Efficacy and Safety of Lonidamine for the Treatment of Symptomatic Benign Prostatic Hyperplasia

NCT00237536
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
Lonidamine
Drug
Lead sponsor
Threshold Pharmaceuticals
Industry
Eligibility
65 Years to 80 Years · Male only
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
34
States / cities
Tucson, Arizona • Atherton, California • Culver City, California + 29 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2009 · Synced Sep 25, 2026, 1:38 PM EDT
Completed Phase 3 Interventional

Clinical Trial in Males With BPH (Enlarged Prostate)

NCT00029822
View directory record Official record
Conditions
Urinary Retention, Prostatic Hyperplasia, Benign Prostatic Hypertrophy
Interventions
Alfuzosin (SL770499)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
55 Years and older · Male only
Enrollment
1,522 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
35
States / cities
Huntsville, Alabama • La Mesa, California • San Bernardino, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2008 · Synced Sep 25, 2026, 1:38 PM EDT
Recruiting Not applicable Interventional

Sacral Neuromodulation for Male Overactive Bladder (MOAB)

NCT06511141
View directory record Official record
Conditions
Overactive Bladder, Urinary Urgency Incontinence, Benign Prostatic Hyperplasia, Prostate Cancer, Prostatectomy, Urinary Frequency
Interventions
Axonics SNM System
Device
Lead sponsor
Axonics, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
23
States / cities
Birmingham, Alabama • Fairhope, Alabama • Scottsdale, Arizona + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2026 · Synced Sep 25, 2026, 1:38 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Compare Giving AVODART And FLOMAX Together Or In A Combination Capsule In The Fed And Fasted State

NCT00537654
View directory record Official record
Conditions
Prostatic Hyperplasia
Interventions
Treatment sequence A, Treatment sequence B, Treatment sequence C, Treatment sequence D
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
81 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
2
States / cities
Evansville, Indiana • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 16, 2017 · Synced Sep 25, 2026, 1:38 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Study of Tadalafil Once-a Day for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia

NCT00384930
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
tadalafil, placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
45 Years and older · Male only
Enrollment
1,058 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Greenwood, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 1, 2009 · Synced Sep 25, 2026, 1:38 PM EDT
Completed No phase listed Observational

SOLTIVE™ Laser Enucleation for Treatment of Benign Prostatic Hyperplasia

NCT04826887
View directory record Official record
Conditions
BPH, Benign Prostatic Hyperplasia
Interventions
SOLTIVE Thulium Laser, Standard of Care (Holmium Laser)
Other
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 1, 2024 · Synced Sep 25, 2026, 1:38 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Urodynamic Feasibility Study Utilizing the UroLift® System

NCT04271020
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
UroLift
Device
Lead sponsor
NeoTract, Inc.
Industry
Eligibility
45 Years and older · Male only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 10, 2020 · Synced Sep 25, 2026, 1:38 PM EDT
Completed Not applicable Interventional Results available

The Value of Multiple Urine Flow Rate Measurements in Male Benign Prostatic Hyperplasia (BPH) Subjects

NCT00710749
View directory record Official record
Conditions
Bladder Outlet Obstruction, Lower Urinary Tract Symptoms
Interventions
Disposable device, Digital device, Clinic flow measurement
Device
Lead sponsor
Wellspect HealthCare
Industry
Eligibility
45 Years to 85 Years · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 10, 2021 · Synced Sep 25, 2026, 1:38 PM EDT
Completed Phase 3 Interventional Results available

A New Drug for Benign Prostatic Hyperplasia (BPH) Compared With Placebo

NCT00224120
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
Silodosin, Placebo
Drug · Other
Lead sponsor
Watson Pharmaceuticals
Industry
Eligibility
50 Years and older · Male only
Enrollment
462 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
42
States / cities
Birmingham, Alabama • Carmichael, California • Fresno, California + 39 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2009 · Synced Sep 25, 2026, 1:38 PM EDT
Withdrawn Early Phase 1 Interventional

Ga-68 MAA Distribution in PAE Patients

NCT04243824
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
Gallium 68 Macro-aggregated albumin
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
40 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 14, 2021 · Synced Sep 25, 2026, 1:38 PM EDT